Ningxia Chinese Medicine Research Center, Yinchuan, China.
School of Pharmacy, Ningxia Medical University, Yinchuan, China.
Pharm Biol. 2022 Dec;60(1):1331-1340. doi: 10.1080/13880209.2022.2093384.
Qiangli Wuhu (QLWH) mixture is a concoction approved and registered by Ningxia Medical Products Administration. It has therapeutic effects on various types of pneumonia.
To clarify the mechanisms of QLWH in treating pneumonia.
The potential targets of QLWH in the treatment of pneumonia were predicted by network pharmacology. Male, Institute of Cancer Research (ICR) mice were randomly divided into five groups of 12 mice, control, vehicle, QLWH (10 and 20 mg/kg) and dexamethasone (DXM), and orally treated twice daily with normal saline, QLWH or DXM. The pneumonia model was established by tracheal instillation of lipopolysaccharide (LPS). After treatment five days, ELISA, H&E staining and Western blot were used to investigate protective effects of QLWH.
Nine hundred and ninety-four active ingredients were found through network pharmacology, corresponding to 135 targets for the treatment of pneumonia; compared to the vehicle group, QLWH (10 and 20 mg/kg) significantly decreased the levels of TNF-α (14.3% and 28.8%), IL-1β (23.9% and 42.8%) and IL-6 (13.2% and 16.1%), increased the levels of IL-10 (134.3% and 172.9%); in terms of mechanism, QLWH down-regulated TLR4/NF-κB/NLRP3 axis related proteins in lung tissue of pneumonia model mice ( < 0.05).
This study combined network pharmacology and animal experiments, providing effective evidence for the clinical promotion of QLWH. Meanwhile, it is of significance for further development.
强力五味丸（QLWH）是由宁夏药品监督管理局批准和注册的方剂，对各种类型的肺炎有治疗作用。
阐明 QLWH 治疗肺炎的作用机制。
通过网络药理学预测 QLWH 治疗肺炎的潜在靶点。雄性，ICR 小鼠随机分为五组，每组 12 只，分别为对照组、溶媒组、QLWH（10 和 20mg/kg）组和地塞米松（DXM）组，分别灌胃给予生理盐水、QLWH 或 DXM，每天两次。通过气管内滴注脂多糖（LPS）建立肺炎模型。治疗 5 天后，采用 ELISA、H&E 染色和 Western blot 法观察 QLWH 的保护作用。
通过网络药理学共发现 994 个活性成分，对应治疗肺炎的 135 个靶点；与溶媒组相比，QLWH（10 和 20mg/kg）显著降低 TNF-α（14.3%和 28.8%）、IL-1β（23.9%和 42.8%）和 IL-6（13.2%和 16.1%）的水平，增加 IL-10（134.3%和 172.9%）的水平；在机制方面，QLWH 下调了肺炎模型小鼠肺组织中 TLR4/NF-κB/NLRP3 轴相关蛋白（ < 0.05）。
本研究结合网络药理学和动物实验，为 QLWH 的临床推广提供了有效证据，同时对进一步开发具有重要意义。
